MBX Biosciences to Participate in Upcoming February Investor Conferences
Rhea-AI Summary
MBX Biosciences (Nasdaq: MBX), a clinical-stage biopharmaceutical company specializing in precision peptide therapies for endocrine and metabolic disorders, has announced its participation in three major investor conferences in February 2025.
The company's President and CEO, Kent Hawryluk, will participate in:
- A fireside chat at the Guggenheim SMID Cap Biotechnology Conference on February 5, 2025 (2:00-2:25 p.m. EST) in New York
- A panel presentation at the BIO CEO & Investor Conference on February 10, 2025 (11:00 a.m.-12:00 p.m. EST) in New York
- A podium presentation at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025 (8:40-9:10 a.m. EST)
Live webcasts will be available on the MBX Biosciences investor website, with replay access available for approximately 90 days after each event.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, MBX gained 8.11%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
CARMEL, Ind., Jan. 23, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at, and participate in, the following upcoming investor conferences:
Guggenheim SMID Cap Biotechnology Conference
Date: Wednesday, February 5, 2025
Format: Fireside Chat
Time: 2:00 - 2:25 p.m. EST
Location: New York, NY
BIO CEO & Investor Conference
Date: Monday, February 10, 2025
Format: Panel Presentation
Time: 11:00 a.m. – 12:00 p.m. EST
Location: New York, NY
Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual)
Date: Tuesday, February 11, 2025
Format: Podium Presentation
Time: 8:40 - 9:10 a.m. EST
Live webcasts can be accessed on the investors section of the MBX Biosciences website at https://investors.mbxbio.com/news-events/events. Access to the webcast replay will be available approximately two hours after the completion of the event and will be archived on the Company’s website for approximately 90 days.
About MBX Biosciences
MBX Biosciences is a biopharmaceutical company focused on the discovery and development of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company’s pipeline includes its lead product candidate MBX 2109, in Phase 2 development for the treatment of chronic hypoparathyroidism (HP); MBX 1416, in Phase 1 development for the treatment of post-bariatric hypoglycemia (PBH); and an obesity portfolio that includes MBX 4291, as well as multiple discovery and pre-clinical candidates in development for the treatment of obesity. The Company is based in Carmel, Indiana. To learn more, please visit the Company website at https://mbxbio.com/ and follow it on LinkedIn.
Media Contact:
Kate Burdick
Inizio Evoke Comms
kate.burdick@inizioevoke.com
860-462-1569
Investor Contact:
Jim DeNike
MBX Biosciences
jdenike@mbxbio.com
FAQ
What investor conferences will MBX Biosciences (MBX) attend in February 2025?
How can investors access MBX Biosciences' February 2025 conference presentations?
What type of presentations will MBX make at each February 2025 conference?
How long will MBX Biosciences' February 2025 conference presentations last?
